Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer (MEDOBREC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2012 by University of Bergen
Sponsor:
Collaborator:
Haukeland University Hospital
Information provided by (Responsible Party):
Per Eystein Lonning, University of Bergen
ClinicalTrials.gov Identifier:
NCT00496795
First received: July 3, 2007
Last updated: May 16, 2012
Last verified: May 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2020
  Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)